TipRanks
pc:lixte

LIXTE Biotechnology

LIXTE Biotechnology is a clinical-stage biotechnology company focused on developing PP2A inhibitors for cancer treatment. Its lead compound, LB-100, is currently in clinical trials for solid tumors, with promising results showing improved survival outcomes in patients with specific genetic mutations. The company collaborates with research institutions to explore the potential of LB-100 in cancer prevention and maintains a diversified balance sheet strategy, including digital assets.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$5M
Total Amount Raised$5M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$5M
Latest Funding Amount$5M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 15, 2025
Investment
$5.00M
―

Similar Companies

A snapshot of private companies similar to LIXTE Biotechnology, helping you discover and navigate related company profiles.

Related News and Analysis